One-carbon Therapeutics has signed a collaboration with Tempus to generate molecular insights aimed at supporting clinical development of its oncology candidate TH9619.

One-carbon Therapeutics said the agreement will use Tempus’ multimodal dataset and bioinformatics tools to better understand tumour biology and inform ongoing development of TH9619, a small-molecule inhibitor targeting one-carbon metabolism pathways in cancer.

The collaboration will focus on analysing RNA sequencing data alongside clinical variables to map expression patterns across selected solid tumour types. The aim is to identify molecular signatures that could help guide clinical strategy and patient selection.

Ana Slipicevic, chief executive officer at One-carbon Therapeutics, said: “Understanding the molecular dynamics of one-carbon metabolism across tumor types and treatment settings is fundamental to advancing TH9619 with precision.” She added that Tempus’ data and analytical capabilities would support the generation of evidence to guide clinical decision making and development.

Tempus will apply its bioinformatics expertise to characterise metabolic signatures across tumour subtypes using its de-identified dataset. The companies said this approach could help refine research strategies and improve understanding of how different cancers depend on one-carbon metabolism.

Ezra Cohen, chief medical officer, oncology, at Tempus, said: “Through comprehensive analysis of our multimodal dataset, we are supporting One-carbon Therapeutics in characterizing the metabolic signatures across diverse tumor types.” He added that these insights are expected to inform development of targeted therapies.

TH9619 is currently being evaluated in the Odin Phase 1/2 trial, a first-in-human study in patients with advanced refractory solid tumours. The study is assessing safety, pharmacokinetics, pharmacodynamics and early anti-tumour activity of the therapy as a monotherapy.

The trial includes patients with colorectal cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, gastric cancer and gastroesophageal junction cancer. It is being conducted across multiple sites in the UK, France and Spain, with further European expansion planned.

TH9619 targets the enzymes MTHFD1 and MTHFD2, which are overexpressed in cancer cells. Inhibiting these enzymes disrupts folate metabolism, leading to depletion of thymidine, a key DNA building block. This process is designed to induce DNA damage and trigger cancer cell death.

The companies said that improving understanding of the biological and genetic features linked to one-carbon metabolism could help identify patients most likely to benefit from treatment. This may also support more efficient clinical development by reducing uncertainty in trial design and execution.

While the collaboration focuses on data analysis and research support, it reflects a broader trend of oncology companies partnering with data and AI-focused groups to strengthen precision medicine approaches. The agreement does not include commercial terms, and its impact will depend on whether the findings translate into measurable clinical outcomes in ongoing and future studies.